Oric Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income | Equity | |
| Balance at December 31, 2023 | 54,865,553 | $6 | $658,751 | $(434,927) | $258 | $224,088 |
| Issuance of common stock, net | 12,500,000 | 1 | 124,831 | — | — | 124,832 |
| Exercise of pre-funded warrants | 2,857,104 | — | — | — | — | — |
| Exercise of common stock options | 152,211 | — | 631 | — | — | 631 |
| Issuance of common stock upon vesting of RSUs | 306,850 | — | — | — | — | — |
| Issuance of common stock from ESPP | 340,137 | — | 1,084 | — | — | 1,084 |
| Stock-based compensation expense | — | — | 20,213 | — | — | 20,213 |
| Unrealized gain on investments | — | — | — | — | 121 | 121 |
| Net loss | — | — | — | (127,847) | — | (127,847) |
| Balance at December 31, 2024 | 71,021,855 | $7 | $805,510 | $(562,774) | $379 | $243,122 |
| Issuance of common stock and pre-funded warrants, net | 25,910,345 | 3 | 241,969 | — | — | 241,972 |
| Exercise of pre-funded warrants | 636,887 | — | — | — | — | — |
| Exercise of common stock options | 390,055 | 1 | 1,978 | — | — | 1,979 |
| Issuance of common stock upon vesting of RSUs | 395,252 | — | — | — | — | — |
| Issuance of common stock from ESPP | 174,555 | — | 1,313 | — | — | 1,313 |
| Stock-based compensation expense | — | — | 25,037 | — | — | 25,037 |
| Unrealized gain on investments | — | — | — | — | 407 | 407 |
| Net loss | — | — | — | (129,468) | — | (129,468) |
| Balance at December 31, 2025 | 98,528,949 | $11 | $1,075,807 | $(692,242) | $786 | $384,362 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.